New Insights Into Anesthetic Mechanisms

Essay

Submitted by

Andrew Yousry Louis

M.B., B.Ch. Faculty of Medicine Ain Shams University

For the partial fulfillment of Master Degree in Anesthesiology

Supervised by

Prof. Dr. Azza Abd Elrashid Hassan

Professor of Anesthesiology Faculty of Medicine Ain Shams University

Dr. Ahmed Mohamed Shafik Hamed

Assistant professor of Anesthesiology Faculty of Medicine Ain Shams University

> Faculty of Medicine Ain Shams University 2013

Acknowledgment

My deepest gratitude and thanks to **Allah** the most merciful for guiding me through and giving me the strength to complete this work.

I would like to express my deepest thanks and profound respect to my honored **Prof. Dr. Azza Abd Elrashid Hassan**, Professor of Anesthesiology for her kind encouragement, guidance, support, and patience she gave me throughout the whole work. It has been an honor and privilege to work under her generous supervision.

I found no words by which I can express my deepest thanks and appreciation to **Dr. Ahmed Mohamed Shafik Hamed,** Assistant professor of Anesthesiology for his great support, valuable time, and continuous advices which helped me to overcome many difficulties.

I finally owe my great thanks and appreciation to **My Parents** who supported me greatly until this work come to light.

Contents

Subject	Page
List of tables.	
List of figures.	III
List of abbreviations.	IV
Introduction.	1
Chapter 1: Ion channels physiology.	4
Chapter 2: Actions of general anesthetics on ion channels.	30
Chapter 3: Actions of local anesthetics on ion channels.	85
Chapter 4: Ion channel disorders.	
Chapter 5: Molecular approaches toward improving anesthetic drugs.	157
Summary.	174
References.	178
Arabic Summary.	

List Of Tables

Table		_
No.	Title	Page
1	Main ion channel types and representative examples	8
2	The four main types of receptors	18
3	Point mutations on the $GABA_{\mbox{\scriptsize A}}$ receptor affecting the effect of GAs	37
4	Susceptibility to block types of nerve fibers	60
5	Sodium ion channel disorders (channelopathies)	77
6	Chloride ion channel disorders (channelopathies)	83
7	Potasium ion channel disorders (channelopathies)	91
8	Calcium ion channel disorders (channelopathies)	98
9	Criteria for the clinical grading scale for malignant hyperthermia	102
10	Correlation between clinical profile and molecular targets of general anesthetics	108

List of Figures

Figure No.	Title	Page
1	The gating of ion channels	4
2	Physiology of ion channels	7
3	Ligand gated ion channels	9
4	Cys-loop ion channel topology	10
5	Diagrammatic representation of the pore-forming subunits of three ion channels	13
6	Receptor classification	17
7	Chemical structures of selected general anesthetics	23
8	Diagrams showing the reaction of Amblyostoma larvae to pressure, in the presence of 2.5% ethanol	26
9	Diagrams showing the two major pathways determining the sleep –wakefulness cycle	31
10	Side view of a similarity model of the GABA _A receptor, subtype $(\alpha 1)2(\beta 2)2\gamma 2$	34
11	View of the same similarity model from the extracellular space towards the intracellular space	35
12	Side view of the AMPA receptor	40
13	View of the AMPA receptor from the extracellular space towards the intracellular space (the 'top' view)	41
14	View of two possible binding positions of halothane to the α1-subunit of a model of the GABA _A receptor	48
15	Structural formulas of selected local anesthetics	56
16	Structure of a Na ⁺ channel α-subunit	63
17	Tetrodotoxin (TTX)-resistant and TTX-sensitive Na+ currents in rat dorsal root ganglion neurons blocked by lidocaine	65
18	Local anesthetics reduce firing frequency in small dorsal root ganglia neurons	71
19	Different sensitivities to local anesthetics of firing frequency	72

μM Micro Mole

2PK Two-pore domain potassium channels

4CmC 4-chloro-m-cresol

5-hydroxy tryptamine receptors type 3

Å Ångstrom

ABD Agonist-Binding Domain

AD Autosomal Dominant

ADNP Activity-Dependent Neuroprotective Protein

ADP Adenosine diphosphate

AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole

proprionic acid

AP Action potential

AR Autosomal Recessive

 AT_{1A} Angiotensin AT_{1A} receptor

ATD Extracellular Amino-Terminal Domain

Atm Atmospheric

ATP Adenosine Triphosphate

BDNF Brain-derived neurotrophic factor

BF Basal Forebrain

BFNC Benign familial neonatal epilepsy

Ca²⁺ Calcium

cAMP Cyclic adenosine monophosphate

cDNA Complementary DNA

CF Cystic fibrosis

Chl Chloroform

CK Creatine Kinase

Cl⁻ Chloride

CNS Central Nervous System

CO₂ Carbon Dioxide

CP Creatine Phosphate

DAG Diacylglycerol

DEKA Amino acid sequence (Asp-Glu-Lys-Ala)

Des Desflurane

DM Dystrophic myopathy

DMPC Dimyristoylphosphatidylcholine

DNA Deoxyribonucleic acid

DRG Dorsal root ganglia

E.N.T. Ear, Nose, and Throat

EC Extracellular (domain)

EC₅₀ Half maximal effective concentration

E_K Nernst potential for potassium

E_{Na} Nernst potential for sodium

Enfl Enflurane

Epo Erythropoietin

E_{rev} Nernest reversal potential

Eth Ethanol

Ether Diethyl ether

Etom Etomidate

GABA_A Gamma amino butyric acid receptor type A

GAs General Anesthetics

GDP Guanosine diphosphate

GPCRs G-protein-coupled receptors

GSK Glycogen synthase kinase

GTP Guanosine triphosphate

H₂ Histamine type 2 receptor

Hal Halothane

HCN3 Potassium/sodium hyperpolarization-activated

cyclic nucleotide-gated channel 3

IC Intracellular (domain)

IC₅₀ Median Inhibitory Concentration

IFM Amino acid sequence (isoleucine–

phenylalanine-methionine)

IL Interleukins

IP3 Inositol triphosphate

Isofl Isoflurane

IVCTs In vitro contraction tests

K⁺ Kalium (Potassium)

KI Potassium iodide

LC Locus coeruleus

LDT Laterodorsal tegmental nuclei

 M_{1-3} Muscarinic M_{1-3} receptor

mEq Milliequivalent

Mexyfl Methoxyflurane

MH Malignant Hyperthermia

mM milliMole

MOC Methoxycarbonyl

MR Magnetic resonance spectroscopy

spectroscopy

ms Millisecond

mV Millivolt

N₂O Nitrous oxide

Na⁺ Natrium (sodium)

nACh Nicotinic acetylcholine

nAChR Nicotinic acetylcholine receptor

nM Nanomole

NMDA N-methyl-D-aspartate

Pa Pascal

pA Pico Ampere

PaCO₂ Partial Pressure of Carbon Dioxide in Arterial

Blood

PaO₂ Partial Pressure of Oxygen in Arterial Blood

PDB Protein Data Bank

pH Potential of Hydrogen - negative 10-base log

(power) of the positive hydrogen ion

concentration; measure of acidity

PHHI Persistent hyperinsulinemic hypoglycemia of

infancy

PI Phosphate (Inorganic)

PND Postnatal day

pKa Negative log of ka (acid dissociation constant)

POCD Postoperative cognitive dysfunction

PONV Postoperative nausea and vomiting

Ppb Pentobarbital

PPT Pedunculopontine tegmental nuclei

Pro Propofol

psi Pound per square inch

QX 314 Quaternary derivative of lidocaine

ROS Reactive oxygen species

Sevo Sevoflurane

SH Src homology

SpO₂ Saturation of Peripheral Oxygen

SR Sarcoplasmic reticulum

SV Spontaneous ventilation

TM Transmembrane (domain)

TM2 Second transmembrane domain

TMN Tuberomammillary nucleus

TNF Tumor necrosis factor α

T-tubule Tranverse tubule

TTX Tetrodotoxin

VLPO ventrolateral pre-optic nucleus

WHO World Health Organization



Over time humankind has employed an array of natural medicines and physical methods to alleviate pain and suffering. Ancient Indian and Chinese texts record the beneficial analgesic effects of cannabis and henbane. In Egypt around 3000 B.C., the opium poppy, hellebore, beer, and the legendary mandrake were used for similar purposes. Other approaches to deal with surgical trauma and pain relied on physical methods such as cold, nerve compression, carotid artery occlusion, or infliction of a cerebral concussion. The effectiveness of these historical agents is unknown but alludes to an ever present need (*Brandt*, 1997).

A new era of anesthesia arose as one of the advancements of the Enlightenment. It began with the isolation of oxygen and the synthesis of nitrous oxide in the 1770's by Joseph Priestley. Initially, nitrous oxide was used solely as an intoxicant. American dentist, Horace Wells was the first to recognize the anesthetizing potential of nitrous oxide; however, his attempt to produce surgical anesthesia in 1845 with this weak anesthetic was a miserable failure (*Brandt*, 1997).

Another compound, known as 'sweet vitriol' by Paracelsus and renamed ether in 1730 by German chemist Frobenius, proved to be more potent. It was used for the first successful public demonstration of surgical anesthesia, conducted by William Thomas Green Morton in Boston in 1846, the year after Wells'

failure. Prior to this, Crawford Long, an American physician practicing in Georgia had performed surgery under ether anesthesia as early as 1842. In 1847, Scottish physician Sir James Young Simpson succeeded in demonstrating anesthesia with chloroform, which had been discovered in 1831 by Souberain, Guthrie and Liebig. Chloroform was used by John Snow to oversee the painless delivery of Queen Victoria's eighth child, Leopold, in 1850 (*Brandt*, 1997).

Fast forward to today, a large number of drugs are available to the modern anesthetist to produce general anesthesia, from intravenously administered hypnotics to halogenated vapors and gaseous agents such as xenon. The intravenous hypnotics, which provide a smooth induction of anesthesia, include barbiturates such as sodium pentothal, introduced in 1934 in America by Lundy; etomidate, introduced and studied by Doenicke in 1973, and propofol, which has been widely accepted since its introduction in 1977. The structures of these disparate agents and others are shown in Fig. 7. This dissertation will take a broad look at the mechanisms of action of both general and local anesthetics and attempt to discriminate where they may overlap and where they may diverge (*Lugli et al.*, 2009).

Research efforts have pursued a reductionist path to approach the difficult problem of assigning the clinical effect of an anesthetic to action at a single biological site. This so-called 'unitary theory' has animated efforts to produce a single molecular definition of the site of anesthetic action. Subsequent research has revealed a multitude of targets and produced a more complex picture of how clinically relevant doses of anesthetics affect molecular targets throughout the central nervous system (CNS). Ironically, in recent years research groups have discovered that a few discrete sites within the CNS may indeed mediate the action of some general anesthetics (*Lugli et al.*, 2009)